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Abstract 
Background: The aim of the present study was to elucidate the effect of teneligliptin on oxidative stress and 
endothelial function in Japanese patients with type 2 diabetes and chronic kidney disease (CKD).
Methods: Forty-five patients with type 2 diabetes and CKD who received sitagliptin for at least 12 months were ran-
domized to either continue sitagliptin (n = 23) or switch to teneligliptin (n = 22) for 24 weeks. The following param-
eters were evaluated at baseline and after 24 weeks of treatment with continued sitagliptin or teneligliptin: blood 
pressure, haemoglobin A1c (HbA1c), estimated glomerular filtration rate (eGFR), urinary albumin excretion, endothe-
lial function by reactive hyperaemia index (RHI; EndoPAT® system), reactive oxygen metabolites (ROMs) measured 
by the d-ROMS test, 8-hydroxy-2′-deoxyguanosine, urinary liver-type fatty acid binding protein (L-FABP), and urinary 
8-isoprostane.
Results: The two groups did not significantly differ with regard to age, male-to-female ratio, duration of diabetes, 
body mass index, HbA1c, eGFR, or urinary albumin excretion levels at baseline. We found no significant differences in 
changes of HbA1c, eGFR, or urinary albumin excretion levels between the two groups after 24 weeks of treatment. 
However, treatment with teneligliptin, but not sitagliptin, significantly improved RHI values and was correlated with 
the percent changes in RHI and d-ROMs.
Conclusions: The present study demonstrated that teneligliptin, can improve endothelial function and reduce renal 
and vascular oxidative stress in patients with type 2 diabetes and CKD, independently of reducing albuminuria or 
improving glucose control.
Trial registration UMIN000017180
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Background
The prevalence of type 2 diabetes is increasing rapidly 
worldwide, affecting an estimated 285 million patients in 
2010 and expected to reach 439 million by 2030 [1]. This 
increase has also been seen in Japan, where the majority 
of the 7.2 million people with diabetes mellitus are aged 
between 20 and 79, and the number of people with dia-
betes mellitus will increase to 10.15 million by 2030 [2, 
3]. Chronic kidney disease (CKD) is common in patients 
with type 2 diabetes mellitus, as well as ischaemic heart 
disease and stroke [4]. In addition, Alan et  al. reported 
that CKD contributes to the development of cardiovas-
cular diseases, and thus it increases the risk of death and 
cardiovascular events [5].
It has been reported that approximately 40  % of 
patients with type 2 diabetes mellitus have elevated 
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urinary albumin excretion consistent with underlying 
renal disease, and 17  % of patients with diabetes have 
CKD [6]. Intensive glycaemic control in type 2 diabetes 
mellitus significantly reduced the primary composite out-
come of microvascular events, mainly as a consequence 
of a reduction in nephropathy [7]. However, options for 
anti-hyperglycaemic agents in such patients are limited 
due to safety and tolerability concerns. Metformin, sul-
fonylureas, and thiazolidinedione are associated with an 
increased incidence of hypoglycaemia, weight gain, and 
lactic acidosis in patients with type 2 diabetes and CKD 
[8]. Therefore, many patients with type 2 diabetes and 
CKD do not achieve or maintain adequate glycaemic 
control.
Teneligliptin, a novel dipeptidyl peptidase-4 (DPP-4) 
inhibitor, is substantially metabolized in the liver, and 
its serum concentration is not affected by even severe 
renal impairment [9]. By contrast, sitagliptin is cleared 
primarily by the kidney, with 80 % of oral doses excreted 
unchanged in the urine [6, 10]. Based on its renal clear-
ance, patients with moderate and severe renal insuffi-
ciency should receive one-half of the usual clinical dose 
(50 or 25 mg daily in Japan) [11]. In the context of phar-
macological characteristics, teneligliptin is advantageous 
in that the dose remains the same independent of renal 
function [8, 12].
There have been no reports on the effects of teneliglip-
tin compared to sitagliptin in terms of protective effects 
on vascular endothelial function, suppression of oxida-
tive stress, and effect on biomarkers of tubulointerstitial 
kidney damage such as liver fatty acid-binding protein 
(L-FABP) [13] in patients with type 2 diabetes and CKD. 
In the present study, we aimed to investigate the effect of 
switching from teneligliptin to sitagliptin for 24 weeks on 
endothelial function, oxidative stress markers, and bio-
markers of tubulointerstitial kidney damage.
Methods
Subjects
Forty-five patients with type 2 diabetes and CKD who 
received sitagliptin for at least 12  months were rand-
omized to either continue sitagliptin (n = 23) or switch 
to teneligliptin (n  =  22) for 24  weeks. All patients had 
visited the Department of Endocrinology and Metabo-
lism, Dokkyo Medical University Hospital on an out-
patient basis for glycaemic control. The entry criteria 
included (1) age  >20  years old, (2) type 2 diabetes with 
a haemoglobin A1c (HbA1c) >6.5 %, (3) CKD [estimated 
glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 or 
microalbuminuria >30 mg/g Cr] [14], and (4) treatment 
with sitagliptin for 1 year or longer. The exclusion criteria 
were (1) type 1 diabetes, (2) severe diabetic complications 
such as ketoacidosis, (3) liver dysfunction, (4) pregnant 
or nursing women and those who might be pregnant, 
(5) chronic heart failure, (6) haemodialysis, (7) a history 
of stroke and cardiovascular events, and (8) any patient 
whom the investigator judged to be inappropriate for 
this study. Patients were given detailed explanations of 
the study protocol. Informed consent was obtained from 
each patient. The study protocol was approved by the 
Ethical Committee of Dokkyo Medical University. The 
trial was registered with the University Hospital Medical 
Information Network (UMIN No. #000017180).
Study protocol
Figure 1 shows a summary of the study protocol. The pre-
sent study was an open-label, prospective, randomized 
study. Patients were randomly divided into two groups: 
the sitagliptin group continued treatment with sitag-
liptin and the teneligliptin group switched treatment to 
teneligliptin at the beginning of the study period. Patients 
in both groups were assessed for the following parame-
ters before the start of the study and 24 weeks after the 
continuation of sitagliptin or switch to teneligliptin. No 
changes were made to the type and dose of glucose-low-
ering drugs, angiotensin converting enzyme inhibitors, 
or angiotensin receptor blockers during the study period 
to avoid possible influences on endothelial function, pro-
duction of oxidative stress, and blood pressure. These 
drugs had been prescribed for at least 12 months before 
the study.
Assessment of endothelial function
Measurement of peripheral vasodilator response with 
a fingertip pulse amplitude tonometry (PAT) device is 
emerging as a useful method to assess vascular function 
[15].
Peripheral endothelial function was assessed by reac-
tive hyperaemia peripheral arterial tonometry (RH-
PAT) using an EndoPAT2000 device (Itamar Medical, 
Caesarea, Israel) as described previously [16]. Briefly, 
a blood pressure cuff was placed on 1 upper arm, while 
the contralateral arm served as a control. PAT probes 
were placed on 1 finger of each hand. After a 5-min 
equilibration period, the cuff was inflated to 60  mmHg 
above the systolic pressure (if systolic blood pressure 
was >140 mmHg) or to 200 mmHg (if systolic blood pres-
sure was  ≤140  mmHg) for 5  min and then deflated to 
induce reactive hyperaemia.
RH-PAT values were assessed at baseline and at 
6  months. Endothelial dysfunction was defined as reac-
tive hyperaemia index (RHI)  <0.670. Previous studies 
have demonstrated that the RH-PAT technology has 
excellent reproducibility [15, 16].
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Derivatives of reactive oxygen metabolites (d‑ROMs) 
evaluation
Oxidative stress is defined as an imbalance between 
the production of reactive oxygen metabolites (ROMs) 
and the removal of reactive oxygen species by a variety 
of endogenous and exogenous antioxidants. In the cur-
rent study, we assessed oxidative stress using a simple 
method for the evaluation of ROMs, the recently devel-
oped d-ROMs test [17]. This assay is relatively inexpen-
sive, can be performed in minutes, and has been used to 
assess the effectiveness of various antioxidant treatment 
strategies [18]. The d-ROMs test evaluates free radical 
activity by measuring serum levels of hydroperoxides 
(Diacron, Grosseto, Italy). The results of the d-ROMs 
test are expressed in arbitrary units, so-called Cara-
telli Units (U.CARR), where 1 U.CARR corresponds to 
0.08 mg/100 ml H2O2 [19].
Other measurements
Venous blood samples and urinary samples were taken in 
the morning after an overnight fast.
We evaluated the following parameters at baseline and 
after 12 and 24  weeks of treatment: HbA1c, eGFR, and 
urinary albumin excretion. HbA1c was measured using 
the automated analyzer “MetaboLead HbA1c” (KYOWA 
MEDEX CO., LTD., Tokyo, Japan). Serum low-density 
lipoprotein cholesterol and high-density lipoprotein cho-
lesterol levels were also measured using standard enzy-
matic methods (MetaboLead HDL-C and MetaboLead 
LDL-C, KYOWA MEDEX CO., LTD., Tokyo, Japan). 
Serum triglyceride levels were measured using enzymatic 
assays (Wako Pure Chemical Industries, Ltd., Osaka). 
Urinary albumin excretion was measured by immuno-
nephelometry using a kit from Roche Diagnostics (Rot-
kreuz, Switzerland). eGFR was calculated as 194 × serum 
creatinine−1.094 × age−0.287 in males, and as 194 × serum 
creatinine−1.094 × age−0.287 × 0.739 in females. L-FABP is 
a urinary biomarker of renal tubular injury and was meas-
ured by a two-step sandwich ELISA assay (LSI Medience 
Corporation, Tokyo, Japan). This biomarker has been 
evaluated previously in relation to diabetic kidney dis-
ease, but the results of different studies were conflicting 
[20–22]. The other oxidative stress markers, 8-hydroxy-
2′-deoxyguanosine (8-OHdG) and 8-isoprostane, which 
were evaluated at baseline and 24 weeks, were measured 
by LSI Medience Corporation.
Statistical analysis
Data are shown as mean  ±  standard deviation. Differ-
ences between continuous variables were analysed by the 
paired t test, unpaired t test, Mann–Whitney U test, and 
Wilcoxon’s matched pairs test as appropriate. Categorical 
variables were compared by the Chi square test. P val-
ues <0.05 were considered significant. All analyses were 
performed using Prism 6 (GraphPad Software, Inc., San 
Diego, CA, USA) or StatMate V (Nihon 3B Scientific Inc., 
Niigata, Japan).
Results
Patients’ clinical data are shown in Table  1. There 
were no significant differences between groups in 
any clinical or biochemical parameter, including the 
number of patients in each group with hypertension, 
being treated for hypertension, with dyslipidaemia, or 
being treated for dyslipidaemia at baseline. After the 
24-weeek treatment period, there were no significant 
differences between the groups in the levels of HbA1c, 
eGFR, and (log) urinary albumin excretion (Fig.  2a–c). 
Moreover, fasting glucose levels, C-peptide, lipid pro-
files, and blood pressure did not differ significantly 
Fig. 1 Study protocol. After outpatients received sitagliptin treatment for a period of 12 months or longer, they were randomized to the sitagliptin 
group, who continued to be treated with sitagliptin, or the teneligliptin group, whose treatment was switched to teneligliptin at the beginning of 
the study period
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before and after treatment in either group (Table  2). 
RHI values significantly improved from 1.49 ±  0.32 to 
1.55 ±  0.29 (P  <  0.01) in the teneligliptin group, while 
in the sitagliptin group, RHI values did not differ signifi-
cantly, from 1.50 ± 0.3 to 1.49 ± 0.31 (Fig. 3a). The per-
cent change in RHI in the teneligliptin group was also 
significantly greater than that in the sitagliptin group 
(Fig.  3b, P  <  0.05). d-ROMs, as a biomarker of oxida-
tive stress, also decreased similarly in the teneliglip-
tin group from 399.8  ±  88.4 to 355.5  ±  92.0 U.CARR 
(P  <  0.01) (Fig.  4a). The percent change in d-ROMs in 
the teneligliptin group was slightly decreased compared 
to that in the sitagliptin group (Fig.  4b). Furthermore, 
8-OHdG was significantly reduced at 24  weeks in the 
teneligliptin group from 7.1 ± 4.9 to 5.4 ± 2.9 ng/m Cre 
(Table 2; P < 0.05) compared with the sitagliptin group 
(6.4 ±  1.5 −  7.4 ±  2.1 ng/mg Cre). Urinary 8-isopros-
tane levels slightly increased in both groups at the 
end of the study, particularly in the sitagliptin group 
when compared to the levels in the teneligliptin group 
(Table 2; P < 0.05).
Baseline values and changes in urine markers of kid-
ney injury (urinary L-FABP) are reported in Table  2. 
Compared with the starting period, teneligliptin, and 
not sitagliptin, was associated with a significant reduc-
tion of urinary L-FABP (P  <  0.05), whereas urinary 
β2-microglobulin and N-acetyl b-d-glucosaminidase lev-
els did not change in either group (data not shown).
Table 1 Clinical characteristics of the subjects at baseline
Data are mean ± SD or median and interquartile range
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor 
blocker
Teneligliptin Sitagliptin P value
Age (years) 70.0 ± 3.9 65.4 ± 10.7 0.912
Sex (M/F) 22 (10/12) 23 (12/11) 0.652
Body mass index (kg/m2) 22.1 ± 3.4 23.6 ± 1.9 0.209
HbA1c  % (NGSP) 8.1 ± 1.4 8.0 ± 1.7 0.739
Duration of diabetes 
(years)
13.2 ± 3.0 12.8 ± 6.3 0.952
eGFR (mL/min/1.73m2) 43.5 ± 15.8 39.6 ± 15.9 0.394
Urinary albumin excre-
tion (µg/g Cre)
418.4 (93.5–299.5) 485.0 (67.0–729.3) 0.750
Statins n (%) 16 (72.7 %) 17 (80.9 %) 0.627
ACEI or ARB n (%) 20 (90.1 %) 20 (95.2 %) 0.578
Biguanide n (%) 3 (13.6 %) 4 (19.0 %) 0.631
Sulfonylurea or glinide 
n (%)
7 (31.8 %) 9 (42.9 %) 0.454
Insulin n (%) 12 (54.5 %) 9 (42.9 %) 0.443
Fig. 2 Changes in HbA1c (a), eGFR (b), and urinary albumin excretion (c). There were no significant differences in the levels of HbA1c, eGFR, and 
urinary albumin excretion between the sitagliptin and teneligliptin treatment groups
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Figure 5 shows the percent changes in RHI (the value at 
the starting of the trial minus that after 24 weeks divided 
by the starting value) upon treatment with teneligliptin, 
but not sitagliptin. The percent change in RHI strongly 
correlated negatively with the percent change in d-ROMs 
in the teneligliptin group (Fig. 5; P < 0.05).
Discussion
The results of the present study showed that 24-week 
teneligliptin treatment improved RHI values, as demon-
strated by the reduction in d-ROMs and urinary 8-OHdG 
levels, in patients with type 2 diabetes and CKD who had 
received sitagliptin for at least 12 months prior to switch-
ing to teneligliptin. In addition, we observed that tenel-
igliptin treatment also reduced urinary L-FABP levels 
regardless of the reduction of urinary albumin excretion. 
These results suggest that the antioxidative and reno-
protective effects of teneligliptin might be stronger than 
those of other DPP-4 inhibitors, particularly sitagliptin, 
and might be independent of its blood glucose-lowering 
effects.
Mori et  al. reported that the DPP-4 inhibitor sitaglip-
tin can prevent progression of diabetic nephropathy by 
reducing the severity of proteinuria and albuminuria [23]. 
However, the mechanism of DPP-4 inhibitor-induced 
improvement of albuminuria is unclear. In the present 
study, since the included patients had already received 
DPP-4 treatment for at least 12 months, urinary albumin 
excretion was not reduced in either the sitagliptin or the 
teneligliptin group. Notably, only switching to teneliglip-
tin, and not sitagliptin continuation, reduced urinary 
L-FABP at 24 weeks.
Urinary L-FABP levels have been reported to associ-
ate with the histological severity of renal tubulointersti-
tial lesions in humans [21, 24]. Although urinary albumin 
excretion appears to reflect glomerular damage and sub-
sequently renal tubulointerstitial damage, recently cases 
of diabetes have been reported in which renal function 
rapidly decreased without an increase in urinary albu-
min excretion [25]. Therefore, Araki et  al. reported that 
urinary L-FABP might reflect tubulointerstitial damage 
and predict the progression of deteriorating renal func-
tion [21]. In addition, increasing urinary L-FABP levels 
were associated with deteriorating renal function and the 
high incidence of atherosclerotic cardiovascular disease 
(ASCVD) in type 2 diabetes. Thus, improvement of uri-
nary L-FABP levels might be clinically useful for patients 
at high risk for renal disease and ASCVD. Urinary L-FABP 
is known to be a renoprotective protein localized predom-
inantly in the proximal tubules, which has antioxidant 
properties and indicates the elevation of oxidative stress 
markers. One of the mechanisms responsible in part for 
the reduction of urinary L-FABP levels by teneligliptin 
treatment might be attenuation of oxidative stress.
In the present study, we also evaluated levels of uri-
nary 8-OHdG to assess the effect of antioxidative stress 
Table 2 Comparison of clinical and biochemical parameters at baseline and 24 weeks
Data are mean ± SD or median and interquartile range
SBP systolic blood pressure, DBP diastolic blood pressure, LDL-C low-density lipoprotein cholesterol, HDL high-density lipoprotein cholesterol, TG triglycerides, eGER 
estimated glomerular filtration rate, 8-OHdG 8-hydroxy-2′-deoxyguanosine, L-FABP liver-type fatty acid binding protein
* P1  value: <0.05, comparison of respective data between baseline and after 24 weeks treatment with teneligliptin
* P2  value: <0.05, comparison of respective data between baseline and after 6 month treatment with sitagliptin
Teneligliptin (n = 22) Sitagliptin (n = 23) P1 value P2 value
Baseline 24 weeks Baseline 24 weeks
HbA1c % (NGSP) 8.1 ± 1.4 8.0 ± 1.2 8.0 ± 1.7 7.9 ± 1.4 0.27 0.39
Fasting glucose (mg/dL) 161.5 ± 49.7 157.7 ± 31.7 150.0 ± 26.3 161.7 ± 33.6 0.8 0.19
C-peptide (ng/mL) 1.8 ± 0.9 2.0 ± 0.6 2.5 ± 1.0 2.5 ± 1.1 0.32 0.33
SBP (mmHg) 133.3 ± 13.4 132.4 ± 14.2 139.1 ± 22.9 131.4 ± 16.8 0.79 0.06
DBP (mmHg) 76.1 ± 11.0 74.0 ± 10.9 79.3 ± 17.0 75.4 ± 12.8 0.5 0.07
LDL-C (mg/dL) 107.1 ± 21.3 105.3 ± 19.4 98.2 ± 21.5 98.7 ± 21.6 0.71 0.91
HDL-C (mg/dL) 53.4 ± 13.2 50.7 ± 12.0 55.5 ± 16.8 50.1 ± 9.1 0.12 0.06
TG (mg/dL) 120.3 ± 41.3 129.3 ± 60.1 156.1 ± 99.9 149.0 ± 70.2 0.51 0.61
eGFR (ml/min−1/1.73 m2) 43.5 ± 15.8 42.8 ± 16.7 39.6 ± 15.9 39.2 ± 16.2 0.36 0.77
Urinary albumin (mg/g Cre) 141.0 (93.5–299.5) 176.0 (84.5-268.0) 141.5 (67.0–729.3) 165.5 (52.8-546.0) 0.58 0.32
Log urinary albumin (mg/g Cre) 2.3 ± 0.5 2.3 ± 0.5 2.3 ± 0.6 2.3 ± 0.6 0.73 0.25
Urinary 8-OHdG (ng/mg Cre) 7.1 ± 4.9 5.4 ± 2.9 6.4 ± 1.5 7.4 ± 2.1 0.03* 0.1
Urinary L-FABP (µg/g Cre) 25.7 (6.3–118.0) 14.5 (7.0–64.9) 48.2 (7.2–91.9) 55.0 (9.6–110.8) 0.02* 0.22
Urinary 8-isoprostane (pg/mgCr) 199.0 (151.5–424.0) 297.0 (212.5–440.0) 258.0 (227.0–429.0) 353.0 (301.0–578.0) 0.06 0.01*
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on tubulointerstitial kidney damage. Urinary 8-OHdG 
levels were slightly increased in both treatment groups, 
whereas urinary 8-OHdG significantly increased from 
baseline values only in the sitagliptin group. Further 
long-term studies are needed for more precise evaluation 
of the effects of teneligliptin on kidney function com-
pared with other DPP-4 inhibitors.
Previous studies have reported that RHI correlates with 
vascular endothelial dysfunction and is a risk factor for 
atherosclerosis and cardiovascular disease [15, 26]. Vari-
ous researchers have reported RHI cutoff values of <1.82 
[27], <1.70 [28] and <1.63 [29] in Japanese patients with 
type 2 diabetes at high risk of atherosclerotic cardio-
vascular disease. The normal range of RHI values still 
remains controversial. Therefore, in this present study, 
the change in RHI values might be an important fac-
tor reflecting endothelial function during teneligliptin 
treatment.
Endo-PAT is a noninvasive, quantitative, and repeat-
able technique that captures a beat-to-beat record-
ing of the finger arterial pulse-wave amplitude with 
pneumatic probes. Therefore, RHI values can be used 
to evaluate vascular condition and treatment efficacy. 
According these previous reports, we used RHI values as 
Fig. 3 Changes in RHI in both groups (a) and the comparison of improvement in RHI (b). Percent change in RHI [RHI after 24 weeks—RHI before 
treatment]/RHI before treatment. RHI values significantly improved in the teneligliptin group; the percent change in RHI was also significantly 
greater in the teneligliptin group. RHI reactive hyperaemia index
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Fig. 4 Changes in d-ROMs in both groups (a); comparison of percent change in d-ROMs (b). Percent change in d-ROMs: [d-ROMs after 24 weeks of 
treatment—d-ROMs before treatment]/baseline d-ROMs value. A biomarker of oxidative stress, d-ROMS, significantly decreased in the teneligliptin 
group. The percent change in d-ROMs in the teneligliptin group was slightly lower than that in the sitagliptin group
Fig. 5 Correlation between percent change in RHI and percent change in d-ROMs in the teneligliptin group. The percent change in RHI strongly 
and negatively correlated with the percent change in d-ROMs in the teneligliptin group (n = 22)
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a reproducible index of endothelial dysfunction. In the 
present study, teneligliptin treatment was associated with 
significant improvement of digitally recorded RHI val-
ues in type 2 diabetes patients with CKD. Clinical trials 
in patients with type 2 diabetes demonstrated that DPP-4 
inhibitors improve endothelial function, as measured by 
reactive hyperaemia peripheral arterial tonometry and 
flow-mediated dilatation [16, 30]. However, in this study, 
we focused on type 2 diabetes patients with chronic kid-
ney disease. We emphasize that this present study is the 
first report to evaluate the efficacy of teneligliptin on 
endothelial function and antioxidative effects of tenel-
igliptin in tubulointerstitium and endothelium com-
pared with sitagliptin in patients with type 2 diabetes and 
chronic kidney disease who are at high risk of ASCVD.
We recently reported that teneligliptin decreased the 
proportion of time in hyperglycaemia and increased the 
proportion of time at normal glucose levels in a 24-h 
period and significantly improved glucose fluctuations 
over 24  h [31]. By contrast, Nonaka et  al. reported that 
100 mg/day sitagliptin, but not 50 mg/day, provided sub-
stantial 24-h glucose lowering effects [32]. The differ-
ences between teneligliptin and sitagliptin observed in 
this study might be due to the fact that the dosage of sit-
agliptin used in Japan (25 mg/day) is much lower. Moreo-
ver, a recent study has shown that teneligliptin has a high 
potency for inhibiting DPP-4 activity compared with 
other DPP-4 inhibitors [33].
We also directly observed antioxidative effects of tenel-
igliptin as demonstrated by decreased levels of d-ROMs, a 
novel global oxidative stress marker that is easy to meas-
ure. In addition, we showed that the reduction of d-ROMs 
levels by teneligliptin treatment was correlated with the 
amelioration of RHI values. These results suggest that 
this effect of teneligliptin might be associated with sup-
pression of glucose fluctuation independently affecting 
renal function. Glucose fluctuation has been reported to 
cause endothelial dysfunction and oxidative stress gen-
eration more than stable high glucose in type 2 diabetes 
patients [34] and in  vitro [35]. Rizzo et  al. also reported 
that the suppression of glycaemic variability is associated 
with reduction of oxidative stress and markers of sys-
temic inflammation in patients with type 2 diabetes [36]. 
Since our study focused on the influence of teneliglip-
tin on oxidative stress markers and endothelial function, 
we measured fasting glucose level and C-peptide but did 
not examine postprandial glucose, glucose fluctuation, 
or inflammatory cytokines. However, we have already 
reported the improvement of glucose fluctuations caused 
by teneligliptin in Japanese patients with type 2 diabetes 
[31]. Furthermore, Kimura et  al. recently demonstrated 
that a structural feature of teneligliptin, specifically hav-
ing a sulphur atom within the molecule, was beneficial 
for radical scavenging. These beneficial effects of tenel-
igliptin may lead to the reduction of oxidative stress [37]. 
Nevertheless, the present study has some limitations. 
First, the randomized clinical trial used open-label, not 
double-blind, administration of the study drug; however, 
the concealment of allocation and the use of an objective 
end-point assessment strengthened the significance of the 
results. Second, the number of participants was relatively 
small, and the study duration was short. Although we 
measured the expression of ICAM-1/VCAM-1 in both the 
sitagliptin and teneligliptin treatment groups, ICAM-1/
VCAM-1 expression did not significantly decrease in 
either the teneligliptin or sitagliptin group. Nakagami et al. 
reported that long-term treatment with teneligliptin sig-
nificantly decreased ICAM-1 expression in hypertensive 
rats and that this effect might be due, in part, to alleviat-
ing inflammation in the vascular system [38]. Longer-term 
clinical trials might be required to verify the effect of tenel-
igliptin on the expression of ICAM-1/VCAM-1 in type 2 
diabetes patients. However, we believe that the significant 
changes in some biomarkers, which indicate antioxidative 
effects, by teneligliptin treatment provide novel evidence 
of DPP-4 inhibitors. Third, the dosage of sitagliptin was 
relatively small, based on the proper dose for Japanese 
patients with type 2 diabetes and CKD. Fourth, we did not 
evaluate the relationship between glucose fluctuation and 
oxidative stress or RHI values.
Finally, we do not know whether the antioxidative 
effects of teneligliptin, as demonstrated in this study, 
could reduce cardiovascular morbidity in type 2 diabe-
tes patients with CKD. The outcomes of trials of DPP-4 
inhibitors, including sitagliptin, saxagliptin, and aloglip-
tin, showed that these agents did not increase or decrease 
the number of major adverse cardiovascular events [39–
42]. Additional information from future experimental 
studies, as well as clinical studies, with regard to tenel-
igliptin is needed to address these results in patients with 
type 2 diabetes and CKD.
Conclusions
In conclusion, the present study demonstrated that tenel-
igliptin exhibits beneficial effects on both oxidative stress 
and endothelial function in Japanese patients with type 2 
diabetes and CKD. These findings suggest that teneliglip-
tin might be more useful than other DPP-4 inhibitors in 
the treatment of type 2 diabetes with CKD.
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